GNRH1 and myeloid sarcoma: While some studies showed increased relapse risk after GnRH agonist use (82–84), others did not find the same evidence (80, 81, 87); however, a recent meta-analysis demonstrated that no difference in risk of MS relapse was found between GnRH agonist and antagonist ART protocols (88).